Rubius Therapeutics has raised $120 million to take two of its off-the-shelf red blood cell therapies into the clinic. The Flagship Pioneering-backed biotech is using its method for expressing ...
Cell therapy is one of the big ideas in biotech. Entrepreneurs have become captivated by possibilities of engineering white blood cells so they can be re-infused into patients and fight cancer. One ...
Rubius Therapeutics went public in 2018 at a $2 billion valuation — the largest biotech stock market debut at that time. On Wednesday, the company — battered down to a market value of $15 million — ...
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. It offers phase 1/2 clinical trial of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results